CoChat
Sign Up
Cited by 88Venomous Animal Envenomation and StudiesHealthcare and Venom ResearchAmphibian and Reptile Biology

The DOI matches its Crossref record; the references it cites are not checked yet.

Snake antivenom: Challenges and alternate approaches

Alangode, Aswathy, Rajan, Karthika, Nair, Bipin G.·2020·Biochemical Pharmacology
DOI 10.1016/j.bcp.2020.114135
Open this paper in CoChat — free account

Abstract

Snake envenomation is still a serious threat to many countries in the world. The only mainstay treatment depends on the administration of animal derived immunoglobulin based antivenom. Significant limitations to these antivenoms are a challenge in the treatment of snake envenomation. Many alternate approaches have been explored to overcome the limitations of antivenom. Exploring alternate approaches like use of bioactive components from plant sources, use of peptide and small molecule inhibitors are some aspects taken towards improving the current limitations of antivenom therapy. However, all these alternate approaches also have many drawbacks which should be improved by more in vitro and in vivo experiments. Here, we review some of the limitations of current antivenom therapy and developments as well as drawbacks of these alternate treatment strategies.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.bcp.2020.114135

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists haven’t been fetched yet

References 92 · Cited by 88

Research works printed but not linked: 95

  1. Chippaux, 1998, Snake-bites: appraisal of the global situation, Bull. World Health Organ., 76, 515
  2. Kasturiratne, 2008, The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths, PLoS Med., 5, 1591, 10.1371/journal.pmed.0050218 · DOI
  3. J.M. Gutiérrez, J.J. Calvete, A.G. Habib, R.A. Harrison, D.J. Williams, D.A. Warrell, Snakebite envenoming, Nat. Rev. Dis. Prim. (2017). · DOI
  4. Gutiérrez, 2016, Understanding and confronting snakebite envenoming: the harvest of cooperation, Toxicon, 109, 51, 10.1016/j.toxicon.2015.11.013 · DOI
  5. Kang, 2011, Enzymatic toxins from snake venom: structural characterization and mechanism of catalysis, FEBS J., 278, 4544, 10.1111/j.1742-4658.2011.08115.x · DOI
  6. McCleary, 2013, Non-enzymatic proteins from snake venoms: a gold mine of pharmacological tools and drug leads, Toxicon, 62, 56, 10.1016/j.toxicon.2012.09.008 · DOI
  7. Waiddyanatha, 2019, Long-term effects of snake envenoming, Toxins (Basel), 11, 1, 10.3390/toxins11040193 · DOI
  8. Bermúdez-Méndez, 2018, Innovative immunization strategies for antivenom development, Toxins (Basel), 10, 1, 10.3390/toxins10110452 · DOI
  9. Chippaux, 1991, Snake venom variability: methods of study results and interpretation, Toxicon, 29, 1279, 10.1016/0041-0101(91)90116-9 · DOI
  10. De Silva, 2016, Adverse reactions to snake antivenom, and their prevention and treatment, Br. J. Clin. Pharmacol., 81, 446, 10.1111/bcp.12739 · DOI
  11. Hoogenboom, 2005, Selecting and screening recombinant antibody libraries, Nat. Biotechnol., 23, 1105, 10.1038/nbt1126 · DOI
  12. Heard, 1999, Antivenom therapy in the Americas, Drugs, 58, 5, 10.2165/00003495-199958010-00002 · DOI
  13. Chippaux, 1998, The development and use of immunotherapy in Africa, Toxicon, 36, 1503, 10.1016/S0041-0101(98)00140-8 · DOI
  14. León, 2013, Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms, Toxicon, 76, 63, 10.1016/j.toxicon.2013.09.010 · DOI
  15. Huang, 2010, Antivenin-related serum sickness, J. Chin. Med. Assoc., 73, 540, 10.1016/S1726-4901(10)70117-9 · DOI
  16. Tibballs, 1994, Premedication for snake antivenom, Med. J. Aust., 160, 4, 10.5694/j.1326-5377.1994.tb138191.x · DOI
  17. de Silva, 2011, Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial, PLoS Med., 8, 10.1371/journal.pmed.1000435 · DOI
  18. Morais, 2018, Antivenom therapy: efficacy of premedication for the prevention of adverse reactions, J. Venom. Anim. Toxins Incl. Trop. Dis., 24, 1, 10.1186/s40409-018-0144-0 · DOI
  19. I. Nuchprayoon, P. Garner, Interventions for preventing reactions to snake antivenom, Cochrane Database Syst. Rev. (1999). · DOI
  20. Habib, 2011, Effect of pre-medication on early adverse reactions following antivenom use in snakebite: a systematic review and meta-analysis, Drug Saf., 34, 869, 10.2165/11592050-000000000-00000 · DOI
  21. Isbister, 2010, Snakebite doesn’t cause disseminated intravascular coagulation: Coagulopathy and thrombotic microangiopathy in snake envenoming, Semin. Thromb. Hemost., 36, 444, 10.1055/s-0030-1254053 · DOI
  22. Maduwage, 2014, Current treatment for venom-induced consumption coagulopathy resulting from snakebite, PLoS Negl. Trop. Dis., 8, 10.1371/journal.pntd.0003220 · DOI
  23. Isbister, 2009, Failure of antivenom to improve recovery in Australian snakebite coagulopathy, Qjm, 102, 563, 10.1093/qjmed/hcp081 · DOI
  24. Isbister, 2009, Procoagulant snake toxins: laboratory studies, diagnosis, and understanding snakebite coagulopathy, Semin. Thromb. Hemost., 35, 93, 10.1055/s-0029-1214152 · DOI
  25. Tanos, 2008, A model for venom-induced consumptive coagulopathy in snake bite, Toxicon, 52, 769, 10.1016/j.toxicon.2008.08.013 · DOI
  26. Gulati, 2013, Effect of Australian elapid venoms on blood coagulation: Australian Snakebite Project (ASP-17), Toxicon, 61, 94, 10.1016/j.toxicon.2012.11.001 · DOI
  27. Mion, 2013, Hemostasis dynamics during coagulopathy resulting from Echis envenomation, Toxicon, 76, 103, 10.1016/j.toxicon.2013.09.003 · DOI
  28. A. Rogalski, C. Soerensen, B. op den Brouw, C. Lister, D. Dashvesky, K. Arbuckle, A. Gloria, C.N. Zdenek, N.R. Casewell, J.M. Gutiérrez, W. Wüster, S.A. Ali, P. Masci, P. Rowley, N. Frank, B.G. Fry, Differential procoagulant effects of saw-scaled viper (Serpentes: Viperidae: Echis) snake venoms on human plasma and the narrow taxonomic ranges of antivenom efficacies, Toxicol. Lett. 280 (2017) 159–170. · DOI
  29. Maduwage, 2014, Snake antivenom for snake venom induced consumption coagulopathy, Cochrane Database Syst. Rev., 2014, 10.1002/14651858.CD011428 · DOI
  30. Gerardo, 2014, Ethical considerations in design of a study to evaluate a US Food and Drug Administration-approved indication: antivenom versus placebo for copperhead envenomation, Clin. Trials, 11, 560, 10.1177/1740774514543538 · DOI
  31. Lister, 2017, Catch a tiger snake by its tail: differential toxicity, co-factor dependence and antivenom efficacy in a procoagulant clade of Australian venomous snakes, Comp. Biochem. Physiol. Part - C Toxicol. Pharmacol., 202, 39, 10.1016/j.cbpc.2017.07.005 · DOI
  32. C.N. Zdenek, B. op den Brouw, D. Dashevsky, A. Gloria, N.J. Youngman, E. Watson, P. Green, C. Hay, N. Dunstan, L. Allen, B.G. Fry, Clinical implications of convergent procoagulant toxicity and differential antivenom efficacy in Australian elapid snake venoms, Toxicol. Lett. 316 (2019) 171–182. · DOI
  33. C.N. Zdenek, C. Hay, K. Arbuckle, T.N.W. Jackson, M.H.A. Bos, B. op den Brouw, J. Debono, L. Allen, N. Dunstan, T. Morley, M. Herrera, J.M. Gutiérrez, D.J. Williams, B.G. Fry, Coagulotoxic effects by brown snake (Pseudonaja) and taipan (Oxyuranus) venoms, and the efficacy of a new antivenom, Toxicol. Vitr. 58 (2019) 97–109. · DOI
  34. Vanuopadath, 2020, Delineating the venom toxin arsenal of Malabar pit viper (Trimeresurus malabaricus) from the Western Ghats of India and evaluating its immunological cross-reactivity and in vitro cytotoxicity, Int. J. Biol. Macromol., 148, 1029, 10.1016/j.ijbiomac.2020.01.226 · DOI
  35. R.R. Senji Laxme, S. Khochare, H.F. de Souza, B. Ahuja, V. Suranse, G. Martin, R. Whitaker, K. Sunagar, Beyond the ‘Big four’: Venom profiling of the medically important yet neglected Indian snakes reveals disturbing antivenom deficiencies, 2019. · DOI
  36. Antúnez, 2010, Antivenomics of Atropoides mexicanus and Atropoides picadoi snake venoms: relationship to the neutralization of toxic and enzymatic activities, J. Venom Res., 1, 8
  37. Gutiérrez, 2010, Impact of regional variation in Bothrops asper snake venom on the design of antivenoms: integrating antivenomics and neutralization approaches, J. Proteome Res., 9, 564, 10.1021/pr9009518 · DOI
  38. Debono, 2019, Clinical implications of differential antivenom efficacy in neutralising coagulotoxicity produced by venoms from species within the arboreal viperid snake genus Trimeresurus, Toxicol. Lett., 316, 35, 10.1016/j.toxlet.2019.09.003 · DOI
  39. Williams, 2018, Clinical studies of the effectiveness and safety of antivenoms, Toxicon., 150, 1, 10.1016/j.toxicon.2018.05.001 · DOI
  40. Knudsen, 2018, Tropical medicine and infectious disease recent advances in next generation snakebite antivenoms, Trop. Med. Infect. Dis., 3, 1
  41. Silva, 2020, Current research into snake antivenoms, their mechanisms of action and applications, Biochem. Soc. Trans., 1
  42. Upasani, 2017, Ethnomedicinal plants used for snakebite in India: a brief overview, Integr. Med. Res., 6, 114, 10.1016/j.imr.2017.03.001 · DOI
  43. Félix-Silva, 2017, Medicinal plants for the treatment of local tissue damage induced by snake venoms: an overview from traditional use to pharmacological evidence, evidence-based complement, Altern. Med., 2017
  44. Vishwanath, 1987, Interaction of phospholipase A2 from Vipera russelli venom with aristolochic acid: a circular dichroism study, Toxicon, 25, 939, 10.1016/0041-0101(87)90156-5 · DOI
  45. Janardhan, 2015, Antisnake venom properties of medicinal plants, Int. J. Pharm. Pharm. Sci., 7, 21
  46. Madhusudan, 2016, Evaluating the inhibitory potential of Withania somnifera on platelet aggregation and inflammation enzymes: an in vitro and in silico study, Pharm. Biol., 54, 1936, 10.3109/13880209.2015.1123729 · DOI
  47. Mukherjee, 2008, Isolation of a snake venom phospholipase A2 (PLA2) inhibitor (AIPLAI) from leaves of Azadirachta indica (Neem): Mechanism of PLA2 inhibition by AIPLAI in vitro condition, Toxicon, 51, 1548, 10.1016/j.toxicon.2008.03.021 · DOI
  48. Almagro, 2019, Phage display libraries for antibody therapeutic discovery and development, Antibodies, 8, 44, 10.3390/antib8030044 · DOI
  49. Kinkawa, 2010, Up-regulation of the expressions of phospholipase A2 inhibitors in the liver of a venomous snake by its own venom phospholipase A2, Biochem. Biophys. Res. Commun., 395, 377, 10.1016/j.bbrc.2010.04.024 · DOI
  50. Gutiérrez, 2009, Experimental pathology of local tissue damage induced by Bothrops asper snake venom, Toxicon, 54, 958, 10.1016/j.toxicon.2009.01.038 · DOI · Paper page
  51. Herrera, 2015, Tissue localization and extracellular matrix degradation by PI, PII and PIII snake venom metalloproteinases: clues on the mechanisms of venom-induced hemorrhage, PLoS Negl. Trop. Dis., 9, 1, 10.1371/journal.pntd.0003731 · DOI
  52. Kini, 2003, Excitement ahead: structure, function and mechanism of snake venom phospholipase A2 enzymes, Toxicon., 42, 827, 10.1016/j.toxicon.2003.11.002 · DOI
  53. Thwin, 2010, Venom neutralization by purified bioactive molecules: Synthetic peptide derivatives of the endogenous PLA2 inhibitory protein PIP (a mini-review), Toxicon., 56, 1275, 10.1016/j.toxicon.2009.12.023 · DOI
  54. Huang, 1998, Characterization of three endogenous peptide inhibitors for multiple metalloproteinases with fibrinogenolytic activity from the venom of Taiwan habu (Trimeresurus mucrosquamatus), Biochem. Biophys. Res. Commun., 248, 562, 10.1006/bbrc.1998.9017 · DOI
  55. Yee, 2017, Snake venom metalloproteinases and their peptide inhibitors from Myanmar Russell’s viper venom, Toxins (Basel), 9
  56. Wagstaff, 2008, Molecular characterisation of endogenous snake venom metalloproteinase inhibitors, Biochem. Biophys. Res. Commun., 365, 650, 10.1016/j.bbrc.2007.11.027 · DOI
  57. Valente, 2001, BJ46a, a snake venom metalloproteinase inhibitor isolation, characterization, cloning and insights into its mechanism of action, Eur. J. Biochem., 268, 3042, 10.1046/j.1432-1327.2001.02199.x · DOI
  58. Williams, 2011, Ending the drought: New strategies for improving the flow of affordable, effective antivenoms in Asia and Africa, J. Proteomics, 74, 1735, 10.1016/j.jprot.2011.05.027 · DOI
  59. Rocha, 2017, Screening for target toxins of the antiophidic protein DM64 through a gel-based interactomics approach, J. Proteomics, 151, 204, 10.1016/j.jprot.2016.05.020 · DOI
  60. Lipps, 1999, Anti-lethal factor from opossum serum is a potent antidote for animal, plant and bacterial toxins, J. Venom. Anim. Toxins., 5, 56, 10.1590/S0104-79301999000100005 · DOI
  61. Claire, 2017, Opossum peptide that can neutralize rattlesnake venom is expressed in Escherichia coli, Physiol. Behav., 176, 139
  62. Drugs, 2011, Varespladib, Am. J. Cardiovasc. Drugs, 11, 137, 10.2165/11533650-000000000-00000 · DOI · Paper page
  63. Vergara, 2014, Eastern coral snake Micrurus fulvius venom toxicity in mice is mainly determined by neurotoxic phospholipases A2, J. Proteomics, 105, 295, 10.1016/j.jprot.2014.02.027 · DOI
  64. Arce-Bejarano, 2014, Intravascular hemolysis induced by the venom of the Eastern coral snake, Micrurus fulvius, in a mouse model: identification of directly hemolytic phospholipases A2, Toxicon, 90, 26, 10.1016/j.toxicon.2014.07.010 · DOI
  65. De Roodt, 2012, Myotoxicity and nephrotoxicity by Micrurus venoms in experimental envenomation, Toxicon, 59, 356, 10.1016/j.toxicon.2011.11.009 · DOI
  66. Lewin, 2018, Delayed LY333013 (oral) and LY315920 (intravenous) reverse severe neurotoxicity and rescue juvenile pigs from lethal doses of micrurus fulvius (eastern coral snake) venom, Toxins (Basel), 10, 10.3390/toxins10110479 · DOI
  67. Lewin, 2016, Varespladib (LY315920) appears to be a potent, broad-spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation, Toxins (Basel), 8, 10.3390/toxins8090248 · DOI
  68. Bittenbinder, 2018, Coagulotoxic cobras: clinical implications of strong anticoagulant actions of african spitting naja venoms that are not neutralised by antivenom but are by LY315920 (varespladib), Toxins (Basel), 10, 10.3390/toxins10120516 · DOI
  69. Wang, 2018, Exploration of the inhibitory potential of varespladib for snakebite envenomation, Molecules, 23
  70. Salvador, 2019, Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920), Sci. Rep., 9, 1, 10.1038/s41598-019-53755-5 · DOI
  71. Gutiérrez, 2020, Varespladib (LY315920) and methyl varespladib (LY333013) abrogate or delay lethality induced by presynaptically acting neurotoxic snake venoms, Toxins (Basel), 12, 10.3390/toxins12020131 · DOI · Paper page
  72. Zdenek, 2020, Anticoagulant activity of black snake (Elapidae: Pseudechis) venoms: mechanisms, potency, and antivenom efficacy, Toxicol. Lett., 330, 176, 10.1016/j.toxlet.2020.05.014 · DOI
  73. Xiao, 2017, Snake venom PLA2, a promising target for broad-spectrum antivenom drug development, Biomed Res. Int., 2017, 10.1155/2017/6592820 · DOI · Paper page
  74. J.M. Gutiérrez, A. Rucavado, Snake venom metalloproteinases: their role in the pathogenesis of local tissue damage, Biochimie 82 (2000) 841–850. · DOI
  75. Gutiérrez, 1984, Pathogenesis of myonecrosis induced by crude venom and a myotoxin of Bothrops asper, Exp. Mol. Pathol., 40, 367, 10.1016/0014-4800(84)90054-6 · DOI
  76. Moreira, 1992, Ultrastructural alterations in mouse capillary blood vessels after experimental injection of venom from the snake Bothrops asper (Terciopelo), Exp. Mol. Pathol., 57, 124, 10.1016/0014-4800(92)90004-U · DOI
  77. B. Lomonte, J. Lundgren, B. Johansson, U. Bagge, The dynamics of local tissue damage induced by Bothrops asper snake venom and myotoxin II on the mouse cremaster muscle: an intravital and electron microscopic study, Toxicon 32 (1994) 41–55. · DOI
  78. Chaves, 1995, Pharmacological study of edema induced by venom of the snake Bothrops asper (terciopelo) in mice, Toxicon, 33, 31, 10.1016/0041-0101(94)00135-U · DOI
  79. Rucavado, 2004, Effect of the metalloproteinase inhibitor batimastat in the systemic toxicity induced by Bothrops asper snake venom: understanding the role of metalloproteinases in envenomation, Toxicon, 43, 417, 10.1016/j.toxicon.2004.01.016 · DOI
  80. Rucavado, 2000, Inhibition of local hemorrhage and dermonecrosis induced by Bothrops asper snake venom: effectiveness of early in situ administration of the peptidomimetic metalloproteinase inhibitor batimastat and the chelating agent CaNa2EDTA, Am. J. Trop. Med. Hyg., 63, 313, 10.4269/ajtmh.2000.63.313 · DOI
  81. Escalante, 2000, Effectiveness of batimastat, a synthetic inhibitor of matrix metalloproteinases, in neutralizing local tissue damage induced by BaP1, a hemorrhagic metalloproteinase from the venom of the snake Bothrops asper, Biochem. Pharmacol., 60, 269, 10.1016/S0006-2952(00)00302-6 · DOI
  82. Howes, 2007, Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators, Toxicon, 49, 734, 10.1016/j.toxicon.2006.11.020 · DOI
  83. Arias, 2017, Peptidomimetic hydroxamate metalloproteinase inhibitors abrogate local and systemic toxicity induced by Echis ocellatus (saw-scaled) snake venom, Toxicon, 132, 40, 10.1016/j.toxicon.2017.04.001 · DOI
  84. Gómez-Betancur, 2019, Perspective on the therapeutics of anti-snake venom, Molecules, 24, 1, 10.3390/molecules24183276 · DOI
  85. S. GP, Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface, Science (80-.), 228 (1985) 1315–1317. · DOI · Paper page
  86. McCafferty, 1990, Phage antibodies: filamentous phage displaying antibody variable domains, Nature, 348, 552, 10.1038/348552a0 · DOI
  87. Cuesta, 2010, Multivalent antibodies: when design surpasses evolution, Trends Biotechnol., 28, 355, 10.1016/j.tibtech.2010.03.007 · DOI
  88. Funayama, 2012, Production of human antibody fragments binding to melittin and phospholipase A2 in Africanised bee venom: minimising venom toxicity, Basic Clin. Pharmacol. Toxicol., 110, 290, 10.1111/j.1742-7843.2011.00821.x · DOI
  89. Ledsgaard, 2018, Antibody cross-reactivity in antivenom research, Toxins (Basel), 10, 1, 10.3390/toxins10100393 · DOI
  90. Jianxin, 1995, Specificity and binding affinity of an anti-crotoxin combinatorial antibody selected from a phage-displayed library, Biochem. Pharmacol., 50, 1969, 10.1016/0006-2952(95)02095-0 · DOI
  91. Gutierrez, 2007, Trends in snakebite envenomation therapy: scientific, technological and public health considerations, Curr. Pharm. Des., 13, 2935, 10.2174/138161207782023784 · DOI
  92. E.C. Roncolato, L.B. Campos, G. Pessenda, L. Costa E Silva, G.P. Furtado, J.E. Barbosa, Phage display as a novel promising antivenom therapy: a review, Toxicon 93 (2015) 79–84. · DOI
  93. Titus, 2019, Application of phage display for the development of a novel inhibitor of PLA2 activity in western cottonmouth venom, Toxicon, 158, S35, 10.1016/j.toxicon.2018.10.124 · DOI
  94. Gutiérrez, 1998, Neutralization of local tissue damage induced by Bothrops asper (terciopelo) snake venom, Toxicon, 36, 1529, 10.1016/S0041-0101(98)00145-7 · DOI
  95. Lalloo, 2003, Snake antivenoms, J. Toxicol. - Clin. Toxicol., 41, 277, 10.1081/CLT-120021113 · DOI

Metadata

Authors
Alangode, A., Rajan, K., & Nair, B. G.
Affiliations
Amrita Vishwa Vidyapeetham (IN)
Corresponding author
Nair, Bipin G.
ORCID
Venue
Biochemical Pharmacology
Publisher
Elsevier BV
Published
2020-11
Volume
181
Pages
114135
ISSN
0006-2952 (ISSN-L)
DOI
10.1016/j.bcp.2020.114135
OpenAlex
W3040064097
Cited by
88
References
92
Citations by year
2026: 17 · 2025: 19 · 2024: 18 · 2023: 14 · 2022: 11 · 2021: 7 · 2020: 1
FWCI
1.18
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Biochemical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Amrita Vishwa Vidyapeetham University
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Venomous Animal Envenomation and Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Healthcare and Venom Research
  • Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Amphibian and Reptile Biology
Keywords
snake antivenom, snakebite, phytochemicals, peptide inhibitors, small molecule inhibitors, venom toxins
MeSH terms
Animals, Antivenins, Humans, Peptides, Snake Bites, Snake Venoms, Snakes, Toxins, Biological, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Snake antivenom: Challenges and alternate approaches. https://app.cochat.ai/papers/10.1016/j.bcp.2020.114135
The paper
Alangode, A., Rajan, K., & Nair, B. G. (2020). Snake antivenom: Challenges and alternate approaches. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2020.114135